REVIRAL LTD has a total of 36 patent applications. It increased the IP activity by 50.0%. Its first patent ever was published in 2012. It filed its patents most often in United Kingdom, United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are CHONGQING FOCHON PHARMACEUTICAL CO LTD, CYTEIR THERAPEUTICS INC and UNIV DE DROIT ET DE LA SANTE DE LILLE 2.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 8 | |
#2 | United States | 5 | |
#3 | WIPO (World Intellectual Property Organization) | 5 | |
#4 | EPO (European Patent Office) | 4 | |
#5 | Canada | 2 | |
#6 | Republic of Korea | 2 | |
#7 | Australia | 1 | |
#8 | Brazil | 1 | |
#9 | Chile | 1 | |
#10 | China | 1 | |
#11 | Hungary | 1 | |
#12 | Mexico | 1 | |
#13 | Peru | 1 | |
#14 | Serbia | 1 | |
#15 | Russian Federation | 1 | |
#16 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Heterocyclic compounds | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Cockerill Stuart | 14 |
#2 | Mathews Neil | 11 |
#3 | Good James | 11 |
#4 | Ward Simon | 10 |
#5 | Lunn Graham | 10 |
#6 | Gascon Simorte Jose Miguel | 10 |
#7 | Paradowski Michael | 10 |
#8 | Cockerill Stuart George | 6 |
#9 | Barrett Matthew | 4 |
#10 | Stuart Cockerill | 2 |
Publication | Filing date | Title |
---|---|---|
GB202102602D0 | Pharmaceutical compounds | |
GB202010409D0 | Pharmaceutical compounds | |
GB202010408D0 | Pharmaceutical compounds | |
GB201915932D0 | Pharmaceutical compounds | |
GB201915273D0 | Pharmaceutical compounds | |
GB201911944D0 | Pharmaceutical compounds | |
GB201721812D0 | Pharmaceutical compounds | |
US2019167683A1 | Pyrimidine derivatives and their use in treating or preventing a respiratory syncytial virus infection | |
GB201711704D0 | Pharmaceutical compounds | |
AU2015329778A1 | Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV) | |
US2014308282A1 | Pharmaceutical compounds |